首页> 美国卫生研究院文献>Clinical Molecular Pathology >Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.
【2h】

Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.

机译:氟康唑与伊曲康唑可预防血液肿瘤学中的真菌感染。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIMS: To compare the efficacy of and tolerance to oral fluconazole and intraconazole in preventing fungal infection in neutropenic patients with haematological malignancies. PATIENTS: 213 consecutive, afebrile adult patients treated with or without autologous stem cell transplantation for haematological malignancies. METHODS: A randomised, double blind, single centre study. Patients were randomly assigned to receive fluconazole 50 mg or itraconazole 100 mg, both twice daily in identical capsules. An intention to treat analysis was performed on 202 patients, 101 in each group. RESULTS: Microbiologically documented systemic fungal infections occurred in four patients in each group. Clinical fungal infection was thought to be present in seven recipients of fluconazole and four of itraconazole. In all 202 patients, 29 proceeded to intravenous amphotericin (amphotericin B), 16 in the fluconazole group and 13 in the itraconazole group. Superficial fungal infection was seen only in three non-compliant patients in the fluconazole group. All these infections were oral. No major differences were noted in the isolates of fungi in mouth washes and fecal samples. Overall mortality was 8.9% (18 deaths; seven in the fluconazole group, 11 in the itraconazole group). Mortality from microbiologically and clinically documented fungal infection was 4.5% (nine deaths; three in the fluconazole group, six in the itraconazole group). Median time to suspected or proven fungal infection was 16 days in both groups. None of these comparisons reached statistical significance (p < 0.05). No major clinical toxicity was noted and compliance was excellent. CONCLUSIONS: In neutropenic patients treated for haematological malignancies with or without autologous stem cell transplantation, fluconazole and itraconazole in low doses result in a similar low frequency of fungal disease. Fluconazole may be the preferable drug because of the smaller number of capsules and lack of need for timing relative to meals.
机译:目的:比较口服氟康唑和内康唑在预防中性粒细胞减少性血液病患者真菌感染中的功效和耐受性。患者:213例连续的发热患者,接受或不接受自体干细胞移植治疗血液系统恶性肿瘤。方法:一项随机,双盲,单中心研究。随机分配患者接受氟康唑50毫克或伊曲康唑100毫克,均在同一胶囊中每日两次。对202位患者(每组101位)进行了治疗意向分析。结果:微生物学记录的系统性真菌感染发生在每组四名患者中。据认为,七例氟康唑和四例伊曲康唑存在临床真菌感染。在所有202例患者中,有29例接受了两性霉素(amphotericin B)静脉注射,氟康唑组为16例,伊曲康唑组为13例。仅在氟康唑组的三名不依从患者中发现了浅表真菌感染。所有这些感染都是口服的。在漱口液和粪便样品中的真菌分离物中未发现主要差异。总死亡率为8.9%(18例死亡;氟康唑组7例,伊曲康唑组11例)。微生物学和临床记录的真菌感染死亡率为4.5%(9例死亡;氟康唑组3例,伊曲康唑组6例)。两组中疑似或确诊真菌感染的中位时间为16天。这些比较均未达到统计学显着性(p <0.05)。没有发现重大的临床毒性,依从性极好。结论:在接受或不接受自体干细胞移植治疗的血液系统恶性肿瘤的中性粒细胞减少患者中,低剂量的氟康唑和伊曲康唑会导致类似的低频真菌病。氟康唑可能是优选的药物,因为胶囊的数量较少并且相对于进餐而言不需要时间安排。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号